Quality-of-life end points in oncology drug trials

ONCOLOGY

Volumn 13, Issue 10, 1999, Pages 1439-1442

  Beitz, Julie ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; FLUOROURACIL; GEMCITABINE; TAMOXIFEN; TAMOXIFEN CITRATE;

CANCER PAIN; CANCER SURVIVAL; CARCINOMA; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; PROGNOSIS; QUALITY OF LIFE; REVIEW; STUDY; TREATMENT OUTCOME; WEIGHT REDUCTION;

CLINICAL TRIALS; HEALTH STATUS; HUMANS; NEOPLASMS; PATIENT ADVOCACY; QUALITY OF LIFE; RESEARCH DESIGN;

EID: 0033364501     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. The WHO QOL Group: The World Health Organization Quality of Life Assessment (WHO QOL): Position paper from the World Health Organization. Soc Sci Med 41(10):1403-1409, 1995.
2. Naughton MJ, Shumaker SA, Anderson RT, et al: Psychological aspects of health-related quality-of-life measurement: Tests and scales, in Spilker B (ed): Quality of Life and Pharmacoeconomics in Clinical Trials, pp 117-131. Philadelphia, Lippincott-Raven, 1996.
3. Johnson JR, Temple R: Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 69:1155-1159, 1985.
4. Beitz J, Gnecco C, Justice R: Quality-of-life end points in cancer clinical trials: The U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr 20:7-9, 1996.
5. Aaronson NK: Methodologic issues in assessing the quality of life of cancer patients. Cancer 67(3;suppl):844-850, 1991.
6. Cella DF, Tulsky DS, Gray G, et al: Functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993.
7. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998.
8. Moore MJ, Osoba D, Murphy K, et al: Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12:689-694, 1994.
9. Tannock IF, Osoba D, Stockier MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996.
10. Melzack R: The McGill pain questionnaire: Major properties and scoring methods. Pain 1:277-299, 1975.
11. Melzack R, Mount BM, Gordon JM: The Brompton mixture vs morphine solution given orally: Effects on pain. Can Med Assoc J 120:435-438, 1979.
12. Food and Drug Administration Oncologic Drugs Advisory Committee Meeting Transcript, September 11, 1996.
13. Immunex Corp., Seattle, Washington: Novantrone (mitoxantrone for injection concentrate) product insert.
14. Gnecco C, Takeuchi M, Koutsoukos A, et al: An FDA reviewer's perspective on statistical analytic issues in the evaluation of oncologic QOL data. Proceedings of the Biopharmaceutical Section 85-90 of the American Statistical Association, Anaheim, California, August, 1997.
15. Eli Lilly and Co., Indianapolis, Indiana: Gemzar (gemcitabine HCl for injection) product insert.
16. Food and Drug Administration Oncologic Drugs Advisory Committee Meeting Transcript, July 24, 1995.